Using engineered T cells to target small cell lung cancer
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer
This study is exploring a new way to treat small cell lung cancer using specially designed immune cells that can find and attack cancer cells, aiming to improve treatment for patients who haven't had success with standard therapies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10903984 on NIH RePORTER |
What this research studies
This research investigates a new treatment for small cell lung cancer (SCLC) by utilizing chimeric antigen receptor T cells (CAR-Ts). These CAR-Ts are specially designed to recognize and attack cancer cells by targeting specific antigens associated with SCLC. The study aims to identify and prioritize novel cell surface antigens that are prevalent in SCLC, which could enhance the effectiveness of the CAR-T therapy. By focusing on the unique immune responses related to autoantibodies in SCLC, this approach seeks to improve patient outcomes where traditional therapies have failed.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer who may benefit from novel immunotherapy approaches.
Not a fit: Patients with other types of lung cancer or those who do not have small cell lung cancer may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment options for patients with small cell lung cancer.
How similar studies have performed: Previous research has shown success with CAR-T therapies in hematological cancers, but this approach for solid tumors like SCLC is still being explored and is considered novel.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Lastwika, Kristin J — Fred Hutchinson Cancer Center
- Study coordinator: Lastwika, Kristin J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.